Poster Listing

Please click on the presentation title to view the posters:

Poster Number	Presenters First Name	Presenters Last Name	Title of Presentation
1	Farsana	Ahmad	Engaging and Curing Active Drug Users of Hepatitis C
2	Olga	Anagnostou	Recent Syringe Sharing, Long Injecting History, Past Incarceration and Not Living with the Family are Independently Associated with Hepatitis C Virus (HCV) Infection among People who Inject Drugs (PWID) in Greece
3	Amber	Arain	Pilot Study: Combining Formal and Peer Education with Fibroscan to Increase HCV Screening and Treatment in Persons Who Inject Drugs
4	Amber	Arain	Uptake for HCV Screening and Treatment in Persons in Opiate Substitution Therapy (POST) in Belgium
5	Elisabeth	Avril	From Awareness to Treatment: A Comprehensive HCV Model of Care
6	Elisabeth	Avril	The Mobile Hepatitis Screening Program: An Innovative Project among People who Use Drugs in Paris Region
7	David	Baker	Treating Hepatitis C, HIV and Opiate Dependency in a Sydney General Practice: Opportunities and Challenges
8	David	Baker	Fibroscan Screening to Detect Advance Liver Disease in People Living with Hepatitis C Attending an Australian General Practice: A Pilot Program
9	Stefan	Bourgeois	The Modelled Impact of Improved Hepatitis C Virus (HCV) Treatment Strategies on HCV Prevalence among People who Inject Drugs (PWIDS) in Belgium
10	Philip	Bruggmann	Access to Hepatitis C Care for Underserved PWID: Provision Rapid Testing and Fibrosis Assessment in Drug Consumption Rooms
11	Philip	Bruggmann	Hepatitis C Virus Prevalence among People who Inject Drugs in Switzerland
12	Tony	Butler	Willingness to be Treated for Hepatitis C among Prisoners: Results from the National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey (NPBBVS)
13	Kerryn	Butler	Hepatitis C and Associated Injecting Risk Behaviours in People Who Inject Drugs
14	Erika	Castro	Standard of Care of Hepatitis C in the Addiction Medicine Clinic Centre St-Martin
15	Erika	Castro	Swiss Data on Hepatitis C Treatment in People who use Drugs: The SAMMSU Cohort
16	Craig	Connelly	Hepatitis C Treatment Access Via a Community Drug Treatment Service
17	Marie	Debrus	Positive Impact of a Community-Based Educational Intervention on Access to HCV Testing in Difficult–To-Reach People who Inject Drugs: Results from the ANRS-AERLI Study
18	John	Dillon	Preferences for Hepatitis C Testing: Application of a Discrete Choice Experiment with Methadone Users in Tayside, Scotland
19	John	Dillon	Can Dried Blood Spot Testing for Hepatitis C in Community Pharmacy Increase Uptake? Interim Reporting of a Quasi-Experimental Study
20	John	Dillon	How do Methadone Users Experience Community Pharmacy? A Qualitative Study to Explore the Important Attributes When Designing a Hepatitis C Virus Testing and Treatment Pathway
21	Sergii	Filippovych	Improving Quality and Scaling Up Access to HCV Treatment for the Most-At-Risk Populations within Resource Limited Settings of Ukraine
22	Emmanuel	Fortier	The Effect of Social Functioning and Living Arrangement on Treatment Intent, Specialist Assessment and Treatment Uptake for Hepatitis C Virus Infection among People with a History of Injecting Drug Use: The ETHOS Study
23	Vincenzo	Fragomeli	Hepatitis B and C Care in the Opiate Substitution Setting - An Integrated Nursing Model of Care
24	Jason	Grebely	High Connectivity is Associated with HIV Co-Infection in the Transmission Network of People with Recent Hepatitis C Virus Infection in Australia
25	Sara	Grummett	Expanding Access to Hepatitis Care among People Who Inject Drugs (PWID): One Year of Fibroscans at the Kirketon Road Centre
26	Behzad	Hajari	Estimating the Burden of Hepatitis C Virus Infection in Iran: How the Enhanced Antiviral Treatments can Prevent the Rising Burden
27	Syune	Hakobyan	HCV Re-Infection in High-Risk People who Inject Drugs
28	Syune	Hakobyan	HCV HIV Co-Infected PWID Treated for HCV at Inner City Clinic
29	Peter	Higgs	Opportunistic Versus Standard Hepatitis B Vaccination for People who Inject Drugs (PWID) in the Supermix Cohort
30	Anne Lindebo	HolmØvrehus	Retention in Care and Testing Uptake are Major Obstacles to DAA Treatment among PWID Even in Integrated Services
31	Behnam	Honarvar	Blood-Borne Hepatitis in Opiate Users in Iran: A Poor Outlook and Urgent need to Change Nationwide Screening Policy
32	Vivian	Hope	Injecting and Drug Use Factors associated with Recent Hepatitis C Infection: New Findings from a National Sample of People Who Injecting Drugs in The United Kingdom (UK)
33	Alexandra	King	Indigenous Peoples in Canada and Hepatitis C – Stigma Deconstructed
34	Alexandra	King	Community-Derived Research Agenda for Indigenous Peoples with Lived Hepatitis C Experience
35	Lise	Lafferty	Identifying the Social Capital of Men in Prison Screening Positive for HCV
36	Michael	Levy	Incident Hepatitis C Cases Detected through a Custodial HCV Treatment Program
37	Gisela	Macphail	The Challenge to Engage the Whole Patient in the Era of Directly Acting Antiviral (DAA) Therapy for Hepatitis C Virus (HCV) Infections
38	Gisela	Macphail	"Fibroscan Days" as a Tool to Patient Engagement in the Cascade of Care for Hepatitis C (HCV)
39	Lisa	Maher	Pregnancy and Contraceptive Use among Young Women Who Inject Drugs in a Hepatitis C Virus Vaccine Preparedness Study
40	Natasha	Martin	HCV Treatment as Prevention for PWID: Is Reinfection Rate a Useful Outcome for Decision-Makers?
41	Natasha	Martin	HCV Transmission among HIV-Positive Men Who have Sex with Men in The UK: Recent Epidemiology and Modelling The Impact of Scaled-Up HCV Antiviral Treatment with New DAAS for Prevention
42	Marianne	Martinello	High Adherence to Short Duration Response-Guided Treatment among People with Recent HCV Infection: The ATAHC II and DARE-C I Studies
43	Mojca	Matičič	A National Multidisciplinary Healthcare Network for Treatment of Hepatitis C in People who Inject Drugs in Slovenia
44	Mojca	Matičič	Strategies to Manage the HCV Disease Burden in Slovenia
45	Tony	McNaughton	CHANGEing the Pharmacotherapy Experience for People who Use Illicit Drugs
46	Rozalyn	Milne	From Principles to Practice: Description of a Novel Equity-Based HCV Primary Care Treatment Model for PWID
47	Alberto	Moriggia	Response to DAA-Based Hepatitis C Treatment on PWUD in Substitution Therapy: First Real-Life Data from Southern Switzerland
48	Meghan	Morris	Historical and Geographical Trends in Incidence of Hepatitis C Virus (HCV) Infection among People who Inject Drugs: The Inc3 Study
49	Dung	Nguyen	Challenges on HCV Management in HCV/HIV Co-Infection Patients - Evidence from Cross-Sectional Study at NHTD (National Hospital of Tropical Diseases Hanoi - Vietnam)
50	Michael	Ninburg	HCV Testing and Linkage for People who Inject Drugs
51	Geert R	obaeys	Telaprevir in Combination with Peginterferon and Ribavirin in Former Injection Drug Users with Chronic Hepatitis C: Findings of the Observational Integrate Study
52	Elizabeth	Peach	Comparison of Self-Reported Blood-Borne Virus Status with Recent Serology Results in a Local High Risk Population of People who Inject Drugs
53	Elizabeth	Peach	Access to Blood-Borne Virus Testing and Treatment in a Local High Risk Population of People who Inject Drugs
54	Elizabeth	Peach	Hazardous Alcohol Use and Concomitant Blood-Borne Virus Infection in a Local Urban Population of People who Inject Drugs: Implications for Approaches to Harm Reduction
55	David	Pieper	Engaging Substance Users in Advocacy Campaigning
56	Leona	Quewezance	Hepatitis C : Is There Hope
57	Homie	Razavi	Modelling the Impact Of Hepatitis C Virus (HCV) Treatment As Prevention Among People Who Inject Drugs (PWIDs) In Australia
58	Andre Jean	Remy	Treatment of the Hepatitis C in Prison in France in 2011-2012: More Patients Treated in Fewer Medical Jailhouse Units : Results of National Practice Survey
59	Andre Jean	Remy	Tools of Screening Viral Hepatitis B or C in Real Life: New French Model of Care
60	Rachel	Sacks-Davis	Associations between Neighbourhood Disadvantage and Prescription Opiate Injection in Montreal, Canada
61	Daniela van	Santen	HIV and Hepatitis C Treatment Uptake among People Who Use Drugs from the Amsterdam Cohort Studies, 1985-2013
62	Jane	Scarborough	Care Provided for Hepatitis C: Congruence Between Patient Self-Identity and Stereotypes Applied by General Practitioners
63	Nick	Scott	Cost-Effectiveness of Treating Chronic Hepatitis C Virus with Direct-Acting Antivirals in People who Inject Drugs in Australia
64	Nikrant	Shrestha	Integrating a Hepatitis C Peer Support Worker in a Public Drug Treatment Clinic
65	Brian	Stephens	Dry Blood Spot (DBS) Testing in Injecting Drug Users
66	Jack	Stone	The Potential Impact of a Hepatitis C Vaccine for People who Inject Drugs: Is a Vaccine needed in the Age of Direct-Acting Antivirals?
67	Jan	Tait	Managed Care Networks Increase HCV Testing and Referral within Community Drug Services
68	Kjersti	Ulstein	Feasibility and Efficacy of Sofosbuvir-Based Regimens for Treatment of HCV-Infection in a Low Threshold Setting
69	Sally	Watkinson	Integrated Hepatitis C Services in Drug and Alcohol Settings Enable Engagement and Access to Care – A Cascade of Care
70	Ioannis	Xynotroulas	Treatment of Intravenous Drug Users (Idus) with Chronic Hepatitis C, Receiving Opioid Replacement with Buprenorphine in Central Greece. Effectiveness, Tolerability and Compliance